Table 2. SLAM members implicated in anti-cancer clinical trials.

SLAM family	Pathology	Treatment type	Treatment name	Study phase	References
SLAMF1	ALL	Oncolytic MV vaccine strains	CAM-70	Preclinical	[28]
	Non-Hodgkin’s lymphoma		MVVAC2NIS	Preclinical	[29]
SLAMF2	CLL	anti-SLAMF2 Ab	WM-63	Phase 1 clinical trial	[35]
	B lymphoma		HuLy-m3	Preclinical	[36]
	MM		1B4	Preclinical	[37]
SLAMF4	Leukemia	2B4 chimeric receptor	2B4-ζ	Preclinical	[57]
SLAMF6	CLL and lymphoma	anti-SLAMF6 Ab	994.1 and 480.12	Preclinical	[67]
	CLL		αSLAMF6 and Ibrutinib	Preclinical	[68]
SLAMF7	MM	CS1-specific peptide	CS1239–247	Preclinical	[75]
		anti-SLAMF7 Ab	HuLuc63	Preclinical	[70, 72]
			Elotuzumab combined to Bortezomib	Preclinical	[71]
			Elotuzumab combined to Bortezomib	Phase 1 clinical trial	[77]
			Elotuzumab combined to Lenalidomide and Dexamethasone	Phase 1 clinical trial	[79]
			Elotuzumab combined to Lenalidomide and Dexamethasone	Phase 3 clinical trial	(ELOQUENT-1, NCT01335399)
	MM with renal impairment	anti-SLAMF7 Ab	10 mg/Kg Elotuzumab, 5-25 mg Lenalidomide and 40 mg Dexamethasone	Phase 1b clinical trial	[81]
	Refractory or relapsed MM	anti-SLAMF7 Ab	Elotuzumab	Phase 1 clinical trial	[76]
			10 or 20 mg Elotuzumab, 25 mg Lenalidomide and 40 mg Dexamethasone	Phase1b-2 clinical trial	[80]
			10 mg/Kg Elotuzumab, 25 mg Lenalidomide and 40 mg Dexamethasone	Phase 3 clinical trial	[82]
			10 mg/Kg Elotuzumab, 1,3 mg Bortezomib and 20 mg Dexamethasone	Phase 2 clinical trial	[78]
			10 mg/Kg Elotuzumab, 200 mg Thalidomide and 40 mg Dexamethasone	Phase 2 clinical trial	[83]
	Elotuzumab in combination with Lenalidomide and Dexamethasone obtained FDA in November 2015

Abbreviations: MM: Multiple Myeloma; CLL: Chronic Lymphocytic Leukemia; ALL: Acute Lymphocytic Leukemia.